Trial Profile
A Phase 2a/2b Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs ID 93 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- 04 Jan 2024 Planned number of patients changed from 900 to 1500.
- 04 Jan 2024 Status changed from planning to not yet recruiting.
- 22 Sep 2015 New trial record